AtomVie Signs Supply Deal with TerraPower Isotopes for Actinium-225

• AtomVie Global Radiopharma has signed a supply agreement with TerraPower Isotopes for the radioisotope Actinium-225.

• The deal supports AtomVie’s CDMO activities and aims to advance clinical and commercial radiopharmaceutical programs.

AtomVie Global Radiopharma has announced a supply agreement with TerraPower Isotopes, LLC to secure access to high-quality Actinium-225 (Ac-225) for its radiopharmaceutical contract development and manufacturing (CDMO) operations.

The agreement aims to strengthen the supply chain for Ac-225-based programs, supporting both early and late-stage development pipelines. AtomVie’s CDMO services span from clinical to commercial supply, and the partnership is expected to add value for pharmaceutical clients seeking to accelerate radiotherapeutic development.

The collaboration is designed to improve flexibility and responsiveness across the entire product lifecycle, especially for targeted radiopharmaceutical therapies in oncology and other indications.

“We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients,” said Bruno Paquin, CEO of AtomVie. “This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply.”

Scott Claunch, President of TerraPower Isotopes, added that the partnership combines TPI’s supply of high-purity Ac-225 with AtomVie’s development and manufacturing infrastructure to advance patient outcomes.